Dr. Hyam I. Levitsky is the executive vice president of research and the chief scientific officer at Juno Therapeutics. Dr. Levitsky is a pioneer in the administration of therapeutic cancer vaccines, especially after high dose chemotherapy and stem cell transplantation. In addition to being a co-inventor (with Glenn Dranoff, M.D.) of the immunotherapy vaccine GVAX, he has focused his investigations on antigen processing and presentation, T cell co-stimulation, T cell priming versus tolerance, and the evolution of tumor-specific immunity during immune reconstitution. Dr. Levitsky is a member of CRI’s Scientific Advisory Council.
Our imaginations are now the major limitation to what can be done.
Let's spread the word about Immunotherapy! Click to share this page with your community.